R3 Igf 1

Definition and Core Overview of R3 IGF-1

R3 IGF-1 is an 83-amino-acid recombinant analogue of human insulin-like growth factor 1 containing a substitution of Glutamic acid for Arginine at position 3 (Arg3 or R3), along with a 13-amino-acid N-terminal peptide extension. This structural alteration dramatically lowers its affinity for endogenous IGF-binding proteins (IGFBPs) while preserving full potency at the IGF-1 receptor, making it a pivotal reagent for studying cellular proliferation, protein synthesis, and metabolic pathways in preclinical laboratory settings.

In native biological systems, standard insulin-like growth factor 1 is rapidly sequestered by circulating IGFBPs (predominantly IGFBP-3), which limits its unbound, bioavailable half-life to mere minutes. By preventing this sequestration, the R3 modification allows researchers to examine sustained receptor binding and prolonged signal transduction in culture media and experimental animal models without requiring continuous micro-infusion.

When sourcing reagents for cellular assays, obtaining high-purity r3 igf 1 ensures that observed mitogenic and anabolic responses stem directly from receptor activation rather than contamination or degraded peptide fragments. PX1 Research supplies this compound strictly as a research-grade lyophilized powder for in vitro and preclinical evaluation.

Molecular Structure and the Arg3 Modification

The molecular architecture of native human IGF-1 consists of a 70-amino-acid single-chain polypeptide with three intrachain disulfide bridges. The R3 variant introduces two distinct biochemical modifications: the replacement of Glu3 with Arg3 (hence 'R3') and the addition of a 13-amino-acid leader sequence at the N-terminus (MFPAMPLLSLFVN).

The Glu3 residue in native IGF-1 forms a critical ionic contact point with the primary binding domain of most IGF-binding proteins. Replicating or altering this site with a positively charged Arginine residue sterically hinders and electrostatically repels IGFBP interaction. Preclinical ligand-binding assays demonstrate that R3 IGF-1 exhibits a greater than 1,000-fold reduction in binding affinity for IGFBPs compared to native IGF-1.

Despite this significant alteration in binding protein interaction, the tertiary conformation surrounding the Type 1 IGF Receptor (IGF-1R) binding pocket remains intact. Consequently, the modified peptide maintains an ED50 potency in stimulating cell growth that equals or exceeds that of native IGF-1, providing an ideal instrument to isolate IGF-1R signaling from carrier protein interference in research protocols.

Receptor Binding and Receptor Kinase Signaling Pathways

At the cellular level, R3 IGF-1 binds to the heterotetrameric Type 1 IGF Receptor (IGF-1R), a transmembrane tyrosine kinase receptor. Binding triggers autophosphorylation of the intracellular beta-subunits, creating docking sites for insulin receptor substrate (IRS) proteins, primarily IRS-1 and IRS-2.

Once IRS-1 is phosphorylated, it activates two primary intracellular cascades: the Phosphoinositide 3-Kinase (PI3K) / Akt pathway and the Mitogen-Activated Protein Kinase (MAPK) / ERK pathway. The PI3K/Akt pathway plays a dominant role in inhibiting apoptosis and stimulating protein translation through downstream effectors such as mammalian target of rapamycin (mTOR) and p70S6 kinase.

Concurrently, activation of the MAPK/ERK signaling cascade stimulates transcription factors associated with cell cycle progression and cellular proliferation. In vitro studies utilizing skeletal muscle cells (such as C2C12 myoblasts) demonstrate that exposure to R3 IGF-1 accelerates myoblast proliferation and accelerates myotube differentiation compared to equimolar concentrations of native IGF-1.

Preclinical Applications and Laboratory Findings

In academic and pharmaceutical research, R3 IGF-1 serves as a cornerstone reagent across several primary investigative domains:

1. **Myogenesis and Muscle Cell Biology:** In C2C12 myoblast culture models, R3 IGF-1 consistently demonstrates enhanced activation of the mTORC1 pathway, leading to increased total protein synthesis, increased amino acid uptake, and reduced rates of proteolysis.

2. **Chondrocyte and Cartilage Regeneration Models:** In vitro cartilage explant studies utilize R3 IGF-1 to analyze proteoglycan synthesis and extracellular matrix deposition in primary chondrocytes.

3. **Neurobiology and Neuronal Survival Assays:** Preclinical rodent models investigating peripheral nerve regeneration and central neuroprotection employ IGF-1 analogues to evaluate axonal growth cone dynamics and resistance to excitotoxic injury.

4. **Cell Culture Media Optimization:** Industrial serum-free media formulations frequently incorporate stable IGF-1 analogues to support high-density cell proliferation in bioprocess research without requiring fetal bovine serum (FBS). Researchers interested in broader growth factor mechanisms can explore related compounds in our all peptides catalog.

Comparative Analysis: R3 IGF-1 vs. Related Growth Factor Analogues

To select the appropriate tool for specific experimental paradigms, researchers frequently compare R3 IGF-1 against alternative peptide analogues and secretagogues within the growth factor class.

While R3 IGF-1 features an 83-amino-acid sequence with reduced IGFBP affinity, IGF-1 DES is a truncated 67-amino-acid variant lacking the first three N-terminal residues. IGF-1 DES exhibits reduced affinity for IGFBPs alongside significantly increased localized potency at the IGF-1R, making it particularly useful for short-duration localized tissue assays. Conversely, splice variants such as PEG-MGF (Pegylated Mechano Growth Factor) operate through distinct downstream mechanisms focused on muscle stem cell (satellite cell) activation rather than direct systemic metabolic regulation.

In studies where endogenous growth factor production is monitored alongside direct receptor stimulation, investigators often cross-reference direct analogues with growth hormone secretagogues like CJC-1295 No DAC. Understanding the distinctions between direct ligand-receptor agonists and secretagogue-induced cascades is crucial for mapping upstream pituitary pathways versus downstream cell surface receptor signaling.

Reconstitution, Buffer Selection, and Laboratory Handling

Achieving consistent, reproducible experimental outcomes requires strict adherence to proper handling and reconstitution protocols for recombinant growth factors.

Lyophilized R3 IGF-1 is inherently hydrophobic and susceptible to non-specific adsorption onto glass or plastic container surfaces. Reconstitution directly in neutral pH phosphate-buffered saline (PBS) or water often leads to aggregation or loss of peptide yield on vial walls. The standard laboratory recommendation involves reconstituting the lyophilized cake in sterile 10 mM to 100 mM acetic acid (pH ~2.7–3.0) to achieve a concentrated stock solution (typically 0.1 to 1.0 mg/mL).

For long-term storage and working assays, stock solutions should be diluted into buffers containing a carrier protein, such as 0.1% Bovine Serum Albumin (BSA) or Human Serum Albumin (HSA). The carrier protein occupies potential non-specific binding sites on labware, maintaining the bioavailable peptide concentration. Aliquots should be stored at -20°C or -80°C to avoid repeated freeze-thaw cycles, which degrade secondary and tertiary peptide structure.

Analytical Verification: HPLC, Mass Spectrometry, and Endotoxin Limits

In high-throughput cell culture or sensitive in vivo rodent assays, minor impurities or bacterial endotoxins can confound experimental data, invalidating research results.

PX1 Research enforces rigorous quality control parameters for every lot of R3 IGF-1. Analytical confirmation requires a two-step verification process:

1. **Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC):** Verifies chemical purity (guaranteed ≥98%). HPLC chromatography confirms the absence of truncated sequences, oxidation products, or aggregated species.

2. **Electrospray Ionization Mass Spectrometry (ESI-MS):** Confirms exact molecular mass match (8,300 to 9,100 Da depending on salt form and modification) to verify sequence accuracy.

3. **Endotoxin Assay (LAL Test):** Because recombinant peptides are synthesized using bacterial expression systems (e.g., E. coli), quantitative Limulus Amebocyte Lysate testing is essential to confirm endotoxin levels fall below strict research thresholds (<0.1 EU/µg). Excess endotoxin can trigger inflammatory responses in cell culture, distorting cytokine profile evaluations. Review complete documentation in our research library.

Sourcing Standards and Wholesale Laboratory Supply

Securing reliable research compounds requires partnering with suppliers that maintain transparent analytical documentation and compliant manufacturing facilities. PX1 Research operates state-of-the-art facilities compliant with Good Manufacturing Practice (GMP) standards, conducting final quality assays through independent ISO 17025 accredited testing laboratories.

Every vial supplied by PX1 Research includes lot-specific Certificate of Analysis (COA) documentation detailing HPLC purity graphs, mass spectrometry spectra, and quantitative endotoxin values. For institutional accounts, university departments, and corporate research teams requiring bulk quantities, custom formulations, or dedicated lot reservations, explore our wholesale account solutions. All orders ship directly from our domestic logistics hubs in California and Arizona with same-day processing for orders placed Monday through Friday.